The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum and ...
Inmagene Biopharmaceuticals merges with Ikena Oncology to form InmageneBio, focusing on IMG-007, an OX40-targeting antibody ...
AusperBio raises $73 million in series B funding to advance Phase II trials of AHB-137, its antisense oligonucleotide therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback